Persistent high levels of circulating effector memory T cells and anti-nuclear antibodies in metastatic melanoma patients who experience durable CRs to immunotherapy after the cessation of treatment.

e21576Background: Checkpoint blockade therapies have dramatically improved the prognosis for metastatic melanoma patients, with overall response rates reported as high as 35%. These regimens have s...